Premium
INTRANODAL TREATMENT WITH IFNΑ‐DENDRITIC CELLS AND RITUXIMAB INDUCES SYSTEMIC CLINICAL RESPONSE AND ENDOGENOUS VACCINATION AGAINST FOLLICULAR LYMPHOMA: FINAL RESULT OF A PHASE I STUDY
Author(s) -
Cox C.,
Castiello L.,
Mattei M.,
Santodonato L.,
D'agostino G.,
Muraro E.,
Martorelli D.,
Lapenta C.,
Di Napoli A.,
Di Landro F.,
Cangemi M.,
Pavan A.,
Castaldo P.,
Hohaus S.,
Donati S.,
Montefiore E.,
Berdini C.,
Borgioni S.,
Carlei D.,
Monque D.,
Ruco L.,
Prosperi D.,
Tafuri A.,
Spadaro F.,
Sestili P.,
Spada M.,
Dolcetti R.,
Santini S.,
Rozera C.,
Arico' E.,
Capone I.,
Belardelli F.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.126_2630
Subject(s) - medicine , elispot , follicular lymphoma , dendritic cell , immunology , in vivo , immunotherapy , rituximab , cd20 , clinical trial , lymphoma , cancer research , t cell , immune system , biology , microbiology and biotechnology